Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Vehicle-Controlled, Phase I Study to Evaluate the Safety and Tolerability of Topically Applied INM-755 Cream on Epidermal Wounds in Healthy Volunteers

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Vehicle-Controlled, Phase I Study to Evaluate the Safety and Tolerability of Topically Applied INM-755 Cream on Epidermal Wounds in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabinol (Primary)
  • Indications Epidermolysis bullosa
  • Focus Adverse reactions
  • Acronyms CHDR1944; Study 102
  • Sponsors InMed Pharmaceuticals

    • Most Recent Events

    • 01 Jan 2025 Results (n=8) published in the European Journal of Pharmaceutical Sciences.
    • 04 Jun 2024 Results of post hoc( (Study 202) and (Study 102) ) explaining Association between clinical and disease characteristics and detectable or undetectable baseline ctDNA in patients with metastatic uveal melanoma, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 08 Sep 2022 According to an InMed Pharmaceuticals media release, enrollment is expected to complete by year end.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top